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Abstract
Background: Comparative data are an important resource for management of integrated care. In
2001, the English Department of Health created 34 cancer networks, broadly serving populations
of half to three million people, to coordinate c a n c e r  s e r v i c e s  a c r o s s  p r o v i d e r s .  W e  h a v e
investigated how national and regional routine data are used by the cancer network management
teams.
Methods:  Telephone interviews using a standardised semi-structured questionnaire were
conducted with 68 participants in 29 cancer network teams. Replies were analysed both
quantitatively and qualitatively.
Results: While most network teams had a formal information strategy, data were used ad hoc
more than regularly, and were not thought to be as influential in network decision making as other
sources of information. Data collection was more prominent in information strategies than data
use. Perceptions of data usefulness were mixed and there were worries over data quality,
relevance, and potential misuse. Participants were receptive to the idea of a new limited dataset
collating comparative data from currently available routine data sources. Few network structural
factors were associated with data use, perceptions of current data, or receptivity to a new dataset.
Conclusion: Comparative data are underused for managing integrated cancer services in England.
Managers would welcome more comparative data, but also desired data to be relevant, quality
assured and contextualised, and for the teams to be better resourced for data use.
Background
In England, a Cancer Plan [1] was published in 2000, set-
ting out organizational developments for cancer care in
the National Health Service, and creating a new system of
34 cancer networks to serve populations of between half
and three million people, so as to integrate services
between hospitals and community care. The networks are
each managed by a team [2] including a Lead Manager,
Lead Clinician, Lead Nurse, and Service Improvement
Lead, along with additional Leads and managers (such as
Pharmaceutical, Research, and Information) as well as
administrative staff.
A national Cancer Information Strategy was also pro-
duced to accompany the Cancer Plan [3]. Among recom-
mendations were that 'monitoring of performance
indicators which relate to the quality of cancer services
delivery, including screening, should form part of the
assessment of individual cancer services.' Currently avail-
able national and regional comparative data on cancer
services may be a potentially important source of informa-
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tion for network teams to fulfil their role. By comparing
against their own network's previous performance, the
performance of other similar networks, and/or national
averages and targets, such data may help the team to guide
key decisions taken by senior management within the
National Health Service, and internal groups (e.g. the net-
work Board and Executive group).
While administrative data have been used in quality assur-
ance [4] and to compare hospital performance, [5] there
has been little research on the availability and use of com-
parative information for management of integrated serv-
ices. Previous studies have suggested that 'hard' data may
not be the most useful or frequently used source of infor-
mation in health services, that data may be inadequate
and lacking in enough contextual detail to enable com-
parison [6] and that other sources of information includ-
ing expertise and personal knowledge might be more
influential in decision making [7,8]. A previous qualita-
tive study conducted by the authors, examining four Can-
cer Networks in England, found that collection of data
was of a higher priority than use of data, and locally col-
lected data was of more use in management decision mak-
ing than nationally aggregated data. In addition, team
members perceived barriers to using data, including lim-
ited accessibility, limited resources and uncertain data
quality. Organizational factors such as roles and remits,
relationships within and without the network, and man-
agement commitment to using information as a develop-
ment tool, also impacted upon the use of 'hard' data
[9,10].
In the current study we sought to find out how useful cur-
rently available national and regional comparative data
are for management of the integrated services across all
the cancer network teams in England. We investigated
how the data are used and the factors that may affect data
use. In addition, we wanted to assess possible reactions to
providing networks with a dataset collating network rele-
vant cancer information from a variety of currently avail-
able routine data sources.
Methods
Cancer networks coordinate hospital and primary care
services that are organizationally linked by their geo-
graphical proximity to each other, and cover populations
approximating to other health administration and politi-
cal boundaries in England (e.g. Strategic Health Authority,
Cancer Registry, and local government boundaries). The
study used telephone interviews of key informants from
the management teams of the cancer networks.
Sample
Following research ethics approval, we sought and
received approval from 30 of the 34 network Board
Chairs. Twenty nine network teams finally participated in
the survey, resulting in 68 individual responses. Reasons
were not given by the five network teams for non-partici-
pation. Lead Managers, Lead Clinicians and Information/
Data Leads were initially approached to be surveyed. In six
networks, we were advised (usually by the Lead Manager)
to survey 'Other' network team roles including two Service
Improvement Leads, a development Manager, a Sector
Performance Manager, and a Macmillan Information
Lead (for palliative care services). These 'other' roles were
usually responsible for network analysis of regional and
national comparative data in addition to, or absence of, a
Network Information and Data Lead; responses from
'Others' were therefore combined with Information/Data
Lead role in the analyses. Seven networks had no Informa-
tion/Data Lead and no other designated role for looking
at data. Two networks had a combined Lead Clinician/
Lead Manager (whom we classified as Lead Managers).
Full interviews were held with 26 Lead Managers, 18 Lead
Clinicians and 24 Information/Data Leads/Others. Three
people were interviewed from 14 network teams, two peo-
ple were interviewed in 11 network teams, and one person
was interviewed in four teams.
Participating networks included rural as well as urban set-
tings, and between three and twelve hospital groups and
associated community care services. All had a network
board including chairman (usually a hospital or commu-
nity service chief executive), a core network team (includ-
ing Lead Manager, Lead Clinician, Lead Nurse and Service
Improvement Lead), executive representatives from each
primary, secondary and tertiary care organisation in the
network, a representative from the local health authority,
a service user (patient or carer) representative, and a mem-
ber of the voluntary sector. In addition, some network
boards included Lead Cancer Clinicians from primary and
secondary/tertiary care providers, a public health repre-
sentative, a human resource representative, medical
school/university representative, financial advisors, and a
member of the regional Cancer Registry.
Procedure
A structured questionnaire was devised based on previous
interviews conducted with four network teams [9,10], a
previous study of cancer networks in London  [11], and
literature on the use of data in health care [7,12]. Advice
was gained also from experts in the fields of organisa-
tional sociology, health psychology, epidemiology, and
statistics, and patient/carer user-representatives. An
explanatory letter, study summary and copy of the ques-
tionnaire were sent to participants in advance of the tele-
phone interview. Interviews were conducted separately by
two research staff and lasted, on average, 30 minutes
(ranging between 6 and 45 minutes).BMC Health Services Research 2007, 7:204 http://www.biomedcentral.com/1472-6963/7/204
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The questionnaire asked about the use of seven data sets
available in England, including Cancer Waiting Times,
Cancer Registry, Hospital Episodes Statistics, Cancer
Standards Peer Review, National Cancer Patient Survey,
Healthcare Commission Acute Hospital Portfolio, and
Minimum Dataset for Palliative Care [13]. In addition,
participants were encouraged to consider any other
national and regional comparative data that they used or
knew of.
Response options for most of the questionnaire items
were yes/no or five or seven point Likert (e.g. ranging from
strongly disagree to strongly agree) and semantic differen-
tial response scales (e.g. ranging from useless to useful).
Participants were able and encouraged to provide addi-
tional feedback and comments throughout the survey
(full questionnaire available on request from the first
author). We also recorded some information on network
structures and contexts directly from the network teams
and from a national cancer data resource [14].
Qualitative responses to open ended questions were tran-
scribed, ordered by question number, and examined to
identify common themes. Once categorized, responses
were content analysed (counting the same or similar
responses) to indicate frequency of beliefs/examples
across participants (i.e. in relation to: sources of data, uses
of data, reasons for sharing data with the Network Board,
and barriers to using data). Qualitative responses also
enabled the identification of answers that had not been
pre-empted in the structured questionnaire (e.g. reasons
for not providing user-groups with data), and provided
elaboration and anecdotal examples to complement the
quantitative data (e.g. reasons for high/low receptivity to
a new comparative data set). Examples and issues arising
from qualitative data have been summarised in the results
and where appropriate, we present the statistical data sup-
ported by participants' comments.
To summarise findings, five point and seven point
response scales were divided into negative, neutral, and
positive responses. Frequencies and percentages refer to
individual level analysis unless stated otherwise. Data
were analysed individually, by role, and aggregated (mean
average response across participants) by network. Differ-
ences between roles are taken to imply general level of
concordance within teams, and substantial differences in
opinions within teams are highlighted. Some correla-
tional analyses (Pearson's r for parametric data and Spear-
man's Rho for non parametric data) were conducted to
identify possible relationships between data use, percep-
tions of data, and organisational factors. However, as
there were only 29 networks and 68 individual partici-
pants, statistical power to detect an effect is weak, and gen-
eral trends are mainly reported.
Results
Data use across the network teams
• Extent of data recognition and use
Two data sets, Cancer Waiting Times and Cancer Registry,
were the data sources most often recognised and most
often reported as being used by the network teams
(Table 1). This was the case across all three roles.
In addition to the seven specified data sources, 60% (41/
68) participants reported using a total of 24 other (identi-
fiable) types of data that enable comparison (with
national averages, and/or across hospital trusts and/or
networks); 20 of these could be allocated to a single
national source (rather than generic data such as clinical
research/evidence-based data) and are specified in
Table 1: Study participants' awareness and use of nationally available data sources.
Aware of Use
Data source Characteristics No. participants % No. participants %
Cancer Waiting Times Database Times for patients referred by general 
practitioners as 'urgent' (216 hospitals)
68 100 66 97
Cancer Registry National linkage of cancer registration with 
death certificates
68 100 63 92
Hospital Episodes Statistics Routine data on NHS patients – 12 million 
episodes per year
67 98 45 66
Cancer Standards Peer Review One-off survey to assess standards in 110 
cancer 'units' and 46 'centres'
64 94 40 58
National Cancer Patient Survey Sample survey of patients discharged from 
172 acute hospital services
56 82 40 58
Minimum Dataset for Palliative 
Care
Staffing and activity of palliative services 49 72 19 27
Healthcare Commission Acute 
Hospital Portfolio
Staffing and facilities in 188 NHS hospital 
trusts
41 60 8 12BMC Health Services Research 2007, 7:204 http://www.biomedcentral.com/1472-6963/7/204
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Table 2. Participants also reported using locally collected
data and local health administration data.
Total use of the seven data sources was positively
(although not significantly) correlated to use of self-
reported additional data sources (Pearson's r = 0.31 p >
0.10) suggesting that low use of the seven data sources
was not a result of dependence on other sources of data,
and that those using fewer of the seven data sources, used
less data generally. At the network team level (mean use
across network respondents) average use was rated, on a
7 point scale, at just over 4 (s.d. = 0.90, range 2.5 to 7)
data sources. Average use was higher amongst Lead Clini-
cians (mean = 4.4) than either Lead Managers (mean =
4.2) or Information/Data Leads and Others (mean = 3.7).
￿ Strategies and routines
Over half the participants (59% 40/68) indicated that
their network team had some sort of formal information
strategy, although only 34% (23/68) thought it covered
issues of local data collection and data use equally. Only
one participant thought their strategy mainly covered data
use, whilst 23% (16/68) indicated that the main focus was
on data collection. There was some disagreement between
respondents within teams (in 9 out of 25 (36%) network
teams that had more than one participant), over whether
an information strategy existed and over the focus of the
strategy. A higher percentage (72%, 13/18) of Lead Clini-
cians thought that the team had an information strategy
than either Lead Managers (54%, 14/26) or Information/
Data Leads and Others (54%, 13/24). Despite having
information strategies only 26% (18/68) participants said
that they were most likely to use data routinely (as
opposed to ad hoc). However, frequency of data use
depended largely on the data source in question with Can-
cer Waiting Times data being looked at weekly, daily and
"almost hourly".
￿ Specific uses
Data were used by network teams for three required activ-
ities [15] – implementing guidance on clinical practice in
cancer services (76%, 52/68 participants indicated use),
service improvement initiatives (66%, 45/68 indicated
use) and to undertake a national peer review of cancer
service standards (44%, 30/68 indicated use). Cancer Reg-
istry data and Hospital Episodes Statistics were most fre-
quently used for implementing Improving Outcomes
Guidance whilst Cancer Waiting Times and Registry data
were most frequently used for service improvement plans.
Participants were also asked to think of other examples of
data use. The most commonly cited general uses included
planning (8 participants), providing supporting evidence
(8 participants), and setting the network picture in a
national context (6 participants). Frequently cited specific
uses included validating and checking other data (e.g.
Cancer Registry and Cancer Waiting Times) (9 partici-
pants), assessing treatment trends (e.g. Hospital Episodes
Statistics) (8 participants), and monitoring waiting times
in order to meet targets (8 participants).
Table 2: Additional nationally available information sources used by the participants
Information Mentions Source Description
National Clinical Audit Support Programme 8 Healthcare Commission Tumour-specific local audits
Secondary analysis of cancer registry data 7 Office of National Statistics National publications of cancer registrations 
and survival.
NatCanSat data 7 National Cancer Services Analysis 
Team
Resource for data on services provision and 
activity.
Cancer screening data 7 NHS Cancer Screening 
Programmes
Breast, cervical, prostate and colon cancer 
screening.
National reports on cancer services 6 National Audit Office Parliamentary reports, with some secondary 
analyses
Professional Body/Royal Colleges 5 Royal College of Surgeons and 
specialty groups
Professional bodies carry out audits.
Smoking cessation data 4 NHS Stop smoking services statistical bulleting 
published annually.
Cancer drugs approvals 4 National Institute for Health and 
Clinical Excellence
Cancer drugs in association with NHS 
National Cancer Director
Web-based Information Learning System (WILS) 4 NHS Cancer Services 
Collaborative
Organisational and tumour specific 
information for managers
Dr Foster 4 Commerical provider Analysing and presentation of NHS data.
Star ratings data 2 Healthcare Commission Performance indicators for monitoring 
health care.
Others with one mention: National Centre for Health Outcomes Development; National confidential enquiry into patient outcome and death; 
Improving Outcomes Guidance data; Gold Standards Framework; Public Health Observatory; Pharmaceuticals utilization data; Pathspeak – 
pathology data; Programme budgeting data; National tracking exercise for investment in cancer services.BMC Health Services Research 2007, 7:204 http://www.biomedcentral.com/1472-6963/7/204
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￿ Dissemination
Dissemination of data to key network stakeholders,
including Board members and cancer patient and carer/
user representatives, was occurring although not consist-
ently within or across teams. Fifty three percent (36/68) of
participants reported that their networks (but not neces-
sarily network team) had provided some national and
regional comparative data to patient and carer user groups
in the past year with Cancer Waiting Times and Cancer
Registry data being the data sources cited most frequently.
Data were unlikely to be disseminated routinely but more
likely in relation to specific initiatives, nationally released
documents, or as and when the users asked for data. The
most frequently cited reasons for not providing data to
user groups were that there were currently no means or
forums to feed data back, or that the user groups were still
developing and deciding their own priorities (see
Table 3). Reasons were similar across roles although Lead
Managers were more likely than other roles to say that
they had not thought about it or got around to it, whilst
Lead Clinicians, Information/Data Leads and Others,
more often said that users had not asked for the data and/
or would not want them anyway.
Fifty four percent of participants (37/68) noted that
national and regional comparative data were discussed at
Board meetings. Data were discussed to: keep board mem-
bers informed; contextualise local/network data; or be set
aside (as problematic). National and regional compara-
tive data were seen to be less influential on average in
guiding strategic decisions taken by the network/network
Board, than other factors and sources of information
including: relationships between decision makers; knowl-
edge, experience and expertise; and locally collected data.
What factors may affect the use of national and regional 
comparative data?
￿ Perceived usefulness
We asked the participants to rank data source usefulness
and found that Waiting Times and Cancer Registry data
were ranked as most useful by the majority of participants.
This apparently related to current network priorities and
national targets:
"the Cancer Waiting Times is a big focus of our work at the
moment but that reflects political priorities"
In addition, five participants noted that locally collected
data were often more useful than national and regional
comparative data due to their specificity and relevance.
Participants were asked to indicate whether national and
regional comparative data enabled the network team to
assess network quality of service. Results indicated a
mixed response with 50% (34/68) indicating that the data
were useful in this way. Fewer Lead Clinicians thought
that the data assessed quality of service compared to Lead
Managers or Information/Data Leads and Others (22%
(4/18) vs 65% (17/26) and 72% (13/18) respectively). At
network team level average perception (out of 5) was just
over 3 (neither agree/nor disagree that currently available
data enables the network team to assess network quality
of service), with 15 networks scoring the midpoint or
lower. Many participants questioned the extent to which
currently available data enabled them to monitor the serv-
ice at the level of multi-disciplinary team (groups of
health professionals at the hospital trust level who are
ultimately responsible for delivering services). Only 35%
(24/68) said that the data were useful at this level. The
most positive attitudes were among Lead Managers (46%
(12/26), saying the data were useful, compared to only
28% (5/18) of Lead Clinicians and 39% (7/18) Informa-
tion/Data Leads/Others respectively.
￿ Perceived barriers
More than half the respondents (57%, 39/68) thought that
people in their network do not generally trust the quality of
available data. This figure was higher amongst Lead Clini-
cians (66.7% 12/18). However, they considered that trust
was increasing. Two thirds (65%, 44/68) thought that peo-
ple in their network worry about how comparative data
could be used, reporting worries of simplification, misin-
terpretation, and suspicion that data could be used against
them (e.g. to withdraw resources). Again, this was most
common amongst Lead Clinicians (83% 15/18). Sixty per-
cent (41/68) of participants thought that the relevance of
some data is not always clear; however, one participant
acknowledged that the data were relevant but said that "we
Table 3: Main reasons for data not having been disseminated to 
user groups
Reason No. of participants 
reporting reason§
No means or forum to present the data to 
user groups
8
User groups are not ready 10
Data are not relevant to user groups 3
Users would not understand the data 3
Users haven't asked for the data/wouldn't 
want it
4
We just haven't thought about it/got 
around to it
4
Other 2
Don't Know 2
N/A 46
§Reasons were given by the participants and were not fixed response 
options. Participants could give more than one answer.BMC Health Services Research 2007, 7:204 http://www.biomedcentral.com/1472-6963/7/204
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are not that clever at using some data". More Lead Clinicians
thought that the data were not relevant (78% 14/18) than
Lead Managers (58% 15/26) or Information/Data Leads/
Others (67% 12/18).
Rather fewer respondents thought that Government priori-
ties prevented them from using data as they would like to,
with just over 35% (24/68) responding "neither/nor" and
the remainder divided fairly equally between agreeing and
disagreeing. In response to an open question around barri-
ers to data use a broader range of issues were also proposed
as preventing respondents from using data as they would
like to, including poor or uncertain data quality (16 partic-
ipants), lack of timeliness and/or being out of date (13 par-
ticipants), general distrust of the data (8 participants), and
not being able to access data sources easily/not receiving
data routinely or automatically (16 participants).
￿ Receptivity to new comparative data
We were particularly interested in what participants
would think about being given a new set of aggregated
cancer data to allow comparisons of performance across
hospitals within their network and nationally. The large
majority (87%, 59/68) thought such a dataset would be a
good rather than bad idea: 81% (55/68) thought it could
be useful for monitoring quality of service at network
level, 78% (53/68) thought it could be useful for monitor-
ing quality of service at hospital trust level, and 88% (60/
68) thought that it could be useful in their role. However,
only half (49%, 33/68) of participants thought that such
as dataset would be welcomed by others, and only 21%
(14/68) thought that the data would be trusted by clini-
cians. Creating a composite measure of 'receptivity to lim-
ited dataset' (mean score of all six items on perceptions of
a new comparative limited dataset), the average score
across network teams was 5.2 out of 7 (with 7 indicating
higher receptivity), but team averages ranged from lowest
2.8 to highest 6.5.
Concerns about the dataset largely related to inadequate
resources: participants expressed concerns about what
such a dataset would mean in the long term and how its
collection would be overseen. They also wanted to know
how labour intensive it would be to analyse it:
"the amount of time it would take to produce, the amount
of time spent collecting and justifying it and the amount of
arguments over it would not be worth it...it would make my
life [as Information/Data Lead] more difficult"
Concerns were also raised about potential misinterpreta-
tion and misuse:
"it could be incredibly damaging [if not contextualised]"
Thus participants made a number of recommendations if
such a dataset were to be accepted and used effectively by
network teams. These included: the importance of consid-
ering contextual detail; the importance of assessing, and
giving assurance about, the quality of the data; and pre-
senting the data as a prompt for further investigation
rather than as a definitive judgment of quality.
Relationships between data use, perceptions, and network context
We examined whether perceptions of usefulness in assess-
ing quality, barriers to using the data, and receptivity to a
new limited dataset, were associated with the use of seven
key data sources by the network team. In addition, we also
examined whether data use and perceptions of data were
associated with individual and organisational network
factors including length of time respondent has been in
their role, presence of an information lead in the network,
cancer population of network area, number of Strategic
Health Authorities (performance management bodies) in
network, number of Primary Care Trusts covered by the
network, number of Hospital Trusts covered by the net-
work, and whether the network crosses Cancer Registry
regional boundaries (see Table 4). We created four com-
posite measures of perceptions of data sets: 'Total use'
(additive score of the number of data sources used, out of
7); 'Assess quality' (mean score of answers to 'Perceptions
of the usefulness of current data to assess quality of net-
work service'); 'Perceived barriers' (mean score of answers
to "People in this network do not trust the quality of the
data" and "People in this cancer network worry about
how data will be used"); and 'Receptivity to limited data-
set' (mean score of all six items on perceptions of a new
comparative limited dataset). Pearson's r correlations
were used for normally distributed interval level data and
Spearmans Rho correlations were used for non non-nor-
mally distributed and ordinal level data. Associations
were examined at individual and network level. Relation-
ship trends and significant associations were the same at
Table 4: Network level correlations: data use, perceptions about 
data use, and organisational contextual factors
12 3 4
1. Total use 1
2. Assess quality -.04 1
3. Perceived barriers .13 -.17 1
4. Limited dataset 
receptivity
-.46* .52** -.37* 1
5. Time in role .24 -.22 .43* -.41*
6. Cancer population -.24 -.04 .21 .13
7. No. of SHAs .06 .07 .08 -.01
8. No. of PCTs .11 .10 .13 .13
9. No. of hospital trusts .14 .29 -.06 .24
10. Crosses Registry region .28 .30 -.06 -.07
11. Presence of Info-Lead -.06 .13 .11 -.06
*p < .05 **p < .01 ***p < .001BMC Health Services Research 2007, 7:204 http://www.biomedcentral.com/1472-6963/7/204
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network and individual level (only network level will be
reported). Small sample sizes led to few significant
findings.
The composite value 'Receptivity to limited dataset' was
negatively correlated with 'Total use' (rho = -0.46, p <
0.05), suggesting that the more data sources currently
used by the team, the less receptive network teams are to
a new dataset. It was also positively associated with 'Assess
quality' (rho = 0.52 p < 0.01) and negatively associated
with 'Perceived barriers' (rho = -0.37 p < 0.05) suggesting
that respondents who perceive that currently available
comparative data allow them to assess service quality, and
perceive few barriers to using the data, are more receptive
to a new dataset.
Small (although non-significant) effects were also seen for
some organisational contextual factors including data use
with: average length time in post (r = .24), cancer popula-
tion size of the network (-.24) and the network crosses a
Registry region (r = .28). No other organisational factors
appeared to be related to data use. Time in post was also
positively correlated with perceived barriers to using data
(rho = .43 p < .05) and negatively correlated with receptiv-
ity to limited dataset (rho = -.41 p < .05) (and this was par-
ticularly so amongst Lead Clinicians).
Discussion
Cancer networks are an important innovation in inte-
grated management of health services in England. How-
ever, the information strategy for cancer [3] addressed
primarily clinical and administrative data within hospi-
tals and at national level, rather than promotion of inte-
grated care through the cancer networks. We identified
information strategies in only just over half the networks.
Participants in our study were concerned about data qual-
ity, and relevance to their particular areas of work. They
were, however, generally receptive to new comparative
data.
Use of the seven national data sets relating to cancer serv-
ices that we described varied from over 90% for Cancer
Waiting Times and Cancer Registry data, to less than 30%
the Healthcare Commission Acute Hospital Portfolio and
Minimum Data Set. Use seemed to be closely related to
current national cancer services targets and directives,
with networks prioritizing data relating to immediate per-
formance issues on which networks could be held
accountable. Similar 'tunnel vision' effects have been
observed in other studies of information use, for example
in performance indicators [16] and the Government's
focus on waiting time targets has been found in other
services to have complex, perhaps unexpected, clinical
impacts [17].
Local data, individual expertise, and organisational and
individual relationships were more important than com-
parative data in decision making and have been shown
elsewhere to be a major influence in healthcare manage-
ment [7,8]. Only half the respondents thought that cur-
rently available national or regional comparative data
enabled them to assess the quality of service in their net-
work and fewer than 40% of respondents always saw the
relevance of currently available data. There needs to be
more discussion between data collation agencies and
those expected to use the data (e.g. managers, decision
makers, policy makers) to ensure that data being collected
include measures that are valuable and useful.
Our respondents were concerned about the quality of
national data sets, and how data may be used. This lack of
trust appeared in the interviews to be most acute amongst
network clinicians. Lead Clinicians more often reported
that data sets were of little use and expressed their lack of
trust in them. Resistance to data use by practitioners has
been well documented [7,18,19]. However, greater use of
data sets can contribute to recognition of their place in
NHS management, while more discussion is needed with
clinicians in supporting their own information needs. Sta-
tistical analysis of the responses from team members is,
however, limited by the size of the samples.
Members in longer serving roles reported more use of data
but also had stronger perceived barriers to using data and
were less receptive to a new limited dataset. These associ-
ations were greater for the Lead Clinicians. Few other
organisational or network contextual factors were associ-
ated with data use or perceptions, and it is possible to sup-
pose that greater encouragement by government to use
datasets for management would be accepted. Cancer net-
works with smaller cancer populations and those crossing
health care administrative boundaries tended to be more
positive towards using data. Other contextual factors, for
example network budgets, management ethos, and team
relationships and structures might be investigated in
future as determinants of information use.
Conclusion
Comparative data are underused for managing integrated
cancer services in England. The priority given by cancer
network managers to collection of data by services, rather
than to the use of data for management, reflected the pri-
orities of central government, which had set targets for
completeness (especially for waiting times) rather than
supporting networks in the more complex role of under-
standing and interpreting available data.
Networks need to be encouraged to develop and use infor-
mation strategies that deal not only with technical issues
and processes of collection, but also with approaches forPublish with BioMed Central    and   every 
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using data and turning it into meaningful information
and action. Increased engagement with data within the
network teams may lead to increased dissemination and
information sharing amongst other cancer network stake-
holders. Promisingly, our results showed that network
team members would be receptive to new comparative
data collating information from currently available data
sources, and would find it useful in their roles. There is
reason to believe that such data would be used if the
teams were better resourced for data management, if the
data were relevant, quality assured and contextualised
with network-specific information.
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